Page last updated: 2024-10-26

dipyridamole and Cystic Fibrosis of Pancreas

dipyridamole has been researched along with Cystic Fibrosis of Pancreas in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, WJ1
Goeckeler-Fried, JL1
Havasi, V1
Chiang, A1
Rowe, SM1
Plyler, ZE1
Hong, JS1
Mazur, M1
Piazza, GA1
Keeton, AB1
White, EL1
Rasmussen, L1
Weissman, AM1
Denny, RA1
Brodsky, JL1
Sorscher, EJ1

Other Studies

1 other study available for dipyridamole and Cystic Fibrosis of Pancreas

ArticleYear
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2016